<?xml version="1.0" encoding="UTF-8"?>
<p>Until recently, the recommended first-line ART regimen in sub-Saharan Africa consisted of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor (2NRTIs+1NNRTI). The combination of tenofovir (TDF), lamivudine (3TC) (or emtricitabine (FTC)) and efavirenz (EFV) is the current treatment of choice. The phasing out of stavudine (D4T) and nevirapine (NVP) was almost complete in 2014 (
 <xref rid="T2" ref-type="table">table 2</xref>). East Africa and Southern Africa are currently rolling out dolutegravir, an integrase inhibitor with a high barrier to resistance.
 <xref rid="R18" ref-type="bibr">18 19</xref> Due to concerns about an increased risk of neural tube defects if taken during pregnancy,
 <xref rid="R20" ref-type="bibr">20</xref> the roll-out to women has been delayed or limited in some settings. Of note, drug stock-outs in the last 12 months were reported by 59 facilities for first-line drugs, and by 45 for second-line drugs (
 <xref rid="T1" ref-type="table">table 1</xref>).
</p>
